[Long-term interferon (IFN), neominophagen C (SNMC) combination therapy of active liver cirrhosis type C].
Possible effects of IFN and SNMC combination therapy for active liver cirrhosis were described. 28 patients with active liver cirrhosis were treated with natural IFN alpha 3-6 MU TIW for 3-17 months (mean, 8 +/- 6). 8 of 28 patients received combination therapy of SNMC (40 ml iv, TIW). 8 (29%) of 28 patients sustained normal ALT levels with no relapse (complete response) which involved 6 patients with persistent lack of serum HCV RNA sequences after IFN therapy. In those 8 patients, 4 had been received combination of SNMC. There were 4 (14%) patients with relative response. Patients with genotype III or IV had significantly higher response to IFN therapy than the patients with genotype II. In active liver cirrhosis, determination of HCV genotype and HCV RNA levels thought to be significant for the indication of IFN therapy, and that combination of SNMC may provide beneficial effect to IFN therapy for active liver cirrhosis.
Iwabuchi
S
S
Second Department of Internal Medicine, St. Marianna University School of Medicine.
Osada
T
T
Takatori
M
M
Yoshida
H
H
D015415:Biomarkers / Q000032:analysis; D003545:Cysteine / Q000008:administration & dosage*; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D005260:Female; D005838:Genotype; D005998:Glycine / Q000008:administration & dosage*; D016174:Hepacivirus / Q000235:genetics; D006526:Hepatitis C / Q000628:therapy*; D006801:Humans; D007372:Interferons / Q000008:administration & dosage*; D008103:Liver Cirrhosis / Q000628:therapy*; D008875:Middle Aged; D009828:Oleanolic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives*; D012367:RNA, Viral / Q000032:analysis
D015415:Biomarkers; D004338:Drug Combinations; D012367:RNA, Viral; D009828:Oleanolic Acid; C009781:neominophagen C; D007372:Interferons; D003545:Cysteine; D005998:Glycine